S2Medical (S2M) Q2 2025 earnings summary

Executive summary

• Net sales for the first half of 2025 reached 6.9 MSEK, more than doubling year-over-year, driven by increased sales from the Abena partnership and higher marketing efforts.

• Operating costs rose as business normalized and marketing investments increased, impacting personnel and external expenses.

• Net profit for the period was 0.2 MSEK, down from 6.9 MSEK last year, mainly due to lower other operating income after a one-time technology sale in 2024.

• The company remains debt-free since 2024, providing a strong financial foundation.

Financial highlights

• Net sales: 6.9 MSEK (2.9 MSEK in H1 2024), up 138% year-over-year.

• Operating result: -0.5 MSEK (7.0 MSEK in H1 2024).

• Net profit: 0.2 MSEK (6.9 MSEK in H1 2024).

• Earnings per share: 0.00 SEK (0.03 SEK in H1 2024).

• Cash flow for the period: 0.3 MSEK (0.0 MSEK in H1 2024).

• Cash and cash equivalents at period end: 1.3 MSEK.

• Equity ratio: 73%.

Outlook and guidance

• Focus remains on growing base sales with healthy margins and introducing products with faster revenue potential.

• Long-term value expected from innovative wound healing and infection control technologies, especially Admercin.

• Strategic partnerships and selective divestments may be pursued to maximize shareholder value.